Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients

被引:4
|
作者
Li, Shuai [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
breast neoplasms; core needle biopsy; surgical sample; Ki-67; change; prognosis; INTERNATIONAL EXPERT CONSENSUS; HER2; STATUS; SURGICAL SPECIMENS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; AMERICAN SOCIETY; KI67; EXPRESSION; WOMEN; INDEX; EXCISION;
D O I
10.3389/fsurg.2022.905575
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background; To investigate the association of Ki-67 change pattern after core needle biopsy (CNB) and prognosis in HR+/HER2- early breast cancer patients. Method: Eligible patients were categorized into three groups: Low group, Elevation group, and High group. Chi-square test and logistic regression analysis were used to compare the clinic-pathological characteristics. Kaplan-Meier method was used to estimate the rates of recurrence-free interval (RFI) and breast cancer-specific survival (BCSS), which were compared via the Log-rank test. Cox proportional hazard analysis was performed to investigate independent prognostic factors. Results: A total of 2,858 patients were included: 1,179 (41.3%), 482 (16.9%), and 1,197 (41.8%) patients were classified into the low, elevation, and high groups, respectively. Age, tumor size, histological grade, lymph-vascular invasion (LVI), and ER level status were associated with Ki-67 change pattern after CNB. With a median follow-up of 53.6 months, the estimated 5-year RFI rates for the low group, elevation, and high groups were 96.4%, 95.3% and 90.9%, respectively (P < 0.001). And 5-year BCSS rates were 99.3%, 98.3% and 96.8%, respectively (P = 0.001). Compared with patients in the low group, patients in the high group had significantly worse RFI (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.16-2.54) in multivariate analysis. Conclusions: Ki-67 change after CNB was associated with prognosis in HR+/HER2- early breast cancer. Patients with Ki-67 high or elevation after CNB had an inferior disease outcome, indicating the necessity of re-evaluating Ki-67 on surgical specimens after CNB.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The Role of Ki-67 in HR+/HER2-Breast Cancer: A Real-World Study of 956 Patients
    Ma, Qin
    Liu, Yao-Bang
    She, Tong
    Liu, Xin-Lan
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 117 - 126
  • [2] The use of Ki67 testing and scoring in HR+, HER2-early breast cancer
    Brown, J.
    Scardo, S.
    Method, M.
    Schlauch, D.
    Misch, A.
    Picard, S.
    Hamilton, E. P.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S315 - S315
  • [3] Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer.
    Crager, Michael
    Wijayawardana, Sameera R.
    Gruver, Aaron M.
    Blacklock, Andrea
    Baehner, Frederick L.
    Russell, Christy
    Sapunar, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with HR+/HER2-early breast cancer: a systematic review and meta-analysis
    Martins-Branco, Diogo
    Molinelli, Chiara
    Marta, Guilherme Nader
    Ameye, Lieveke
    Paesmans, Marianne
    Salgado, Roberto
    Aftimos, Philippe
    de Azambuja, Evandro
    CANCER RESEARCH, 2023, 83 (05)
  • [5] The Reliability of Core-Needle Biopsy in Assessment of Hormone Receptor, HER2, and Ki-67 in Breast Carcinoma
    Ueno, Nozomi
    Kuroda, Hajime
    Abe, Akihito
    Kubota, Keiichi
    Kato, Hiroyuki
    Imai, Yasuo
    INTERNATIONAL SURGERY, 2017, 102 (11-12) : 522 - 529
  • [6] Ki-67 Evaluation in HR+/HER2-Node-Positive High Risk Early Breast Cancer on Patients Eligible for Abemaciclib Using Artificial Intelligence
    Yasmeen, Sayeeda
    Amin, Al
    Bshara, Wiam
    Desouki, Mohamed
    Khoury, Thaer
    LABORATORY INVESTIGATION, 2023, 103 (03) : S235 - S235
  • [7] Use of the gene expression test Prosigna® in premenopausal patients with HR+, HER2-early breast cancer: Correlation of the results with the proliferation marker Ki-67
    Ziegler, Cordula
    Sotlar, Karl
    Hofmann, Daniel Maria
    Kolben, Thomas
    Harbeck, Nadia
    Wuerstlein, Rachel
    BREAST CARE, 2024, 19 (01) : 34 - 42
  • [8] Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer
    Ni, Hua
    Kumbrink, Joerg
    Mayr, Doris
    Seiler, Alina
    Hagemann, Friederike
    Degenhardt, Tom
    Sagebiel, Sabine
    Wuerstlein, Rachel
    Kates, Ronald
    Harbeck, Nadia
    Eggersmann, Tanja K.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [9] A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2-early breast cancer in the United States
    Brown, Jacqueline
    Scardo, Savannah
    Method, Michael
    Schlauch, Dan
    Misch, Amanda
    Picard, Shaita
    Hamilton, Erika
    Jones, Suzanne
    Burris, Howard
    Spigel, David
    BMC CANCER, 2022, 22 (01)
  • [10] A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States
    Jacqueline Brown
    Savannah Scardo
    Michael Method
    Dan Schlauch
    Amanda Misch
    Shaita Picard
    Erika Hamilton
    Suzanne Jones
    Howard Burris
    David Spigel
    BMC Cancer, 22